BioNexus Gene Lab Becomes First Nasdaq-Listed Firm to Prioritize Ethereum in Treasury Strategy
BioNexus Gene Lab (BGLC) has adopted an Ethereum-focused treasury strategy, thus becoming the first Nasdaq-listed company to prioritize ETH.
The exact percentage for its Ethereum allocation has not been divulged by the company but the move follows the leading altcoins inclusion in the US Crypto Strategic Reserve.
BGLC Embraces Ethereum
BGLC has released its Ethereum Strategy Whitepaper, which details ETHs advantages as a financial infrastructure asset. The focus is also on Ethereums role in stablecoin settlements, decentralized finance (DeFi), and its potential as a corporate treasury asset.
The document sheds light on Ethereums institutional adoption, staking rewards, and upcoming upgrades that boost its long-term value and corporate utility.
The Boards decision was driven by Ethereums increasing credibility among financial institutions, its Proof-of-Stake (PoS) yield-generation capabilities, and its dominance in stablecoin transactions. Upcoming Ethereum protocol upgrades, such as the Pectra update, are expected to improve its efficiency and adoption further.
Additionally, Wyomings blockchain-friendly regulations appear to have influenced BGLCs strategy, according to the press release. As a Wyoming-incorporated company, BGLC benefits from the states progressive legal framework supporting digital assets, including the recent Wyoming Stable Token Act.
In an official statement, the CEO of the company, Sam Tan, said,
By integrating Ethereum into our corporate treasury, BioNexus Gene Lab Corp. is embracing the future of financial infrastructure. Ethereum offers high liquidity, utility, and stability compared to other digital assets, positioning BGLC as a leader in blockchain-integrated corporate finance. Wyomings regulatory leadership further validates our decision, as it fosters an environment where blockchain businesses can thrive.
Ethereum Undervalued
President Donald Trump made a shocking announcement to add Ethereum XRP, Solana, and Cardano to a national crypto reserve alongside Bitcoin. After a brief rally, the prices of the tokens tanked. Ethereum, for one, plunged to $2,032 its lowest level in 16 months before staging a recovery.
The recent market downturn has pushed the altcoin into an undervalued zone, as per the Market Value to Realized Value (MVRV) ratio, which dropped below 1. CryptoQuant explained that, historically, such levels have marked strong buying opportunities, often preceding significant price uptrends.
Further on-chain data shows a surge in ETH accumulation addresses wallets that receive ETH without withdrawing which hints that institutional investors are actively acquiring at these low price levels.
Meanwhile, the realized price of whale investors is concentrated around $2.2$2.3K, which is acting as a critical support level where buying pressure may counteract further declines.
The post BioNexus Gene Lab Becomes First Nasdaq-Listed Firm to Prioritize Ethereum in Treasury Strategy appeared first on CryptoPotato.
Text source: CryptoPotato
